Red cell volume measurement - using indium as a replacement for chromium.

The withdrawal of Cr-chromate has meant that the technique commonly used for direct measurement of red cell volume has had to be replaced. Most centres moved to a Tc erythrocyte label, however, Tc is known to dissociate over time. We have investigated an alternative technique using an In-chloride and tropolone solution and tested this both in vitro and in vivo. Initial in-vitro and in-vivo work, which included a check of the stability of the radio-labelled product at one hour, demonstrated this label to be stable over this time period. To date, 20 patients have undergone this technique and results show that this technique is a viable alternative to Cr-chromate particularly for patients with splenomegaly who require late sampling. This procedure is now in routine use in our institution.

Development and validation of a full model of a four-headed neuroimaging single-photon emission computed tomography scanner.

OBJECTIVE: The Nucline X-Ring 4R is a four-headed gamma camera dedicated to neuroimaging. In this paper, we describe and validate a GATE (Geant4 Application for Tomographic Emission) model of the Nucline X-Ring 4R. MATERIALS AND METHODS: Images produced during model simulations were compared with those acquired experimentally to confirm the model was an accurate representation of the scanner. The most commonly reported measurements used to validate a GATE model include energy resolution, spatial resolution and sensitivity. In addition to the commonly reported static imaging measures, single-photon emission computed tomography (SPECT) spatial resolution was investigated to confirm that the model produces similar SPECT images to the experimental output. RESULTS: The experimental full-width at half-maximum was calculated to be 12.3 keV, which corresponds to an energy resolution of 8.8%. The simulated full-width at half-maximum was measured to be 12 keV, giving an energy resolution of 8.6%. The average spatial resolutions were found to be well matched (5.69 mm - simulated and 5.64 mm - experimental). However, the sensitivity was overestimated using the GATE model (47.8 and 54.3 cps/MBq) compared with the values obtained experimentally (42.7 and 44.3 cps/MBq). Finally, the simulated SPECT spatial resolution images were found to produce qualitatively comparable results. CONCLUSION: The model developed has been shown to produce similar results and images to those obtained experimentally. This model has the potential to simulate patient scans with the aim of improving patient care by optimizing scanner protocols.

Improvement to visualization of nodes in breast cancer patients following audit: are we seeing the problem?

Successful localization of nodes in breast cancer patients depends upon the effectiveness of the lymphoscintigraphy technique employed. A benefit of performing imaging as part of this procedure is that it allows sites to audit their technique. An audit of breast cancer patients at the Glasgow Royal Infirmary (GRI) hospital showed nodes to be visualized in only 81% of patients. Current guidelines state that nodes should be seen in more than 95% of patients. A period of investigation and review led to changes being made to the injection and imaging technique employed at the GRI site. Following these changes a re-audit was performed that showed that the node visualization rate has successfully been increased to 97%, thereby meeting the standards set in the guidelines. This technical note details the results of the initial audit and re-audit, and explains the investigation and changes made to clinical procedures at the GRI site to improve the node visualization rate. The challenges that can occur when performing breast sentinel node procedures are also discussed.

Dual-isotope subtraction SPECT-CT in parathyroid localization.

OBJECTIVE: The aim of this study was to investigate the accuracy of locating parathyroid adenomas using dual-Isotope subtraction single-photon emission computed tomography-computed tomography (SPECT-CT) in comparison with clinical follow-up and pathology findings from surgery. PATIENTS AND METHODS: A retrospective cohort study of dual-isotope subtraction SPECT-CT was carried out on 224 consecutive patients who were diagnosed with primary hyperparathyroidism. All the patients were injected with 20 MBq of iodine-123-iodide, followed 20 min later by 900 MBq of technetium-99m-sestamibi. Planar neck and chest views and SPECT-CT images were acquired 15 min after administration, followed by an additional planar image set at 2 h to view washout; all images were dual energy. In all, 115 out of 224 of the patients imaged underwent parathyroid surgery. The imaging results were compared with pathology findings when available and, in those who did not undergo surgery, and in some complex cases, with clinical measures after a 2-year clinical follow-up period. FINDINGS: Out of the 224 patients, 135 patients had complete pathology and/or clinical follow-up data and were included in the analysis. The sensitivity of the subtraction SPECT-CT findings was measured to be 95%, with a specificity of 89% for the detection and localization of parathyroid adenomas. The positive predictive value was found to be 97% and the negative predictive value was found to be 83%. The accuracy of the technique was 94% in detecting parathyroid adenoma and 92% in accurate localization. CONCLUSION: Dual-isotope subtraction SPECT-CT imaging has a very high sensitivity and specificity in detecting and locating a parathyroid adenoma, showing that it is a very reliable preoperative imaging technique in primary hyperparathyroidism.

White cell and marrow imaging: subtracting uncertainty.

A subtraction method for assessments of dual-isotope indium-111 (In)-labelled white cell and Tc-nanocoll was proposed, and following a pilot study was introduced in routine service to improve the confidence of reporters. This technical note describes a simple technique to produce subtraction images from routinely acquired images to investigate and exclude post joint replacement infection. Labelled leucocytes (with In) show areas of increased white cell accumulation, whereas Tc-nanocoll images show bone marrow distribution. Images resulting from the subtraction protocol highlight any areas of white cell activity which is not concurrent with the marrow distribution indicative of infection. Fusion images produced from these images sets also assists in localization of white cell accumulation(s). Key to the success of this technique is the use of simultaneous acquisition of both white cell and marrow images; thus removing any issues with patient movement and/or repositioning. Reporting clinicians convey a clear preference for the inclusion of the subtracted and fused images at clinical review.

Effect of perindopril on cerebral and renal perfusion on normotensives in mild early ischaemic stroke: a randomized controlled trial.

BACKGROUND AND PURPOSE: Blood pressure reduction is central to secondary prevention after stroke, but the optimal time to start therapy is unknown. Cerebral autoregulation is impaired early after ischaemic insult, and any changes in systemic blood pressure may be reflected in cerebral perfusion. However, early initiation in hospital may better assure continued long-term treatment. We have investigated the effect of the angiotensin-converting enzyme inhibitor perindopril on blood pressure, global and focal cerebral blood flow (CBF) and glomerular filtration rate (GFR) in a normotensive acute stroke population. METHODS: Twenty-five patients within 4-8 days of mild ischaemic stroke/transient ischaemic attack and with diastolic blood pressure 70-90 mm Hg were randomized to receive perindopril 2 or 4 mg daily versus placebo according to estimated GFR. Mean arterial blood pressure (MABP), internal carotid artery (ICA) flow and middle cerebral artery velocity (MCAv) were measured prior to dosing, over the following 24 h and at 2 weeks. Brain hexamethyl propylene amino oxide single photon emission computed tomography (SPECT) was performed before dosing and at estimated time of peak drug effect (6-8 h after first dose). GFR measurement using a (51)Cr-ethylene diamine tetraacetic acid technique was undertaken prior to medication and repeated at 2 weeks. RESULTS: MABP was reduced throughout the first 24 h with a mean MABP reduction of 9.3 mm Hg (95% CI 7.4-11.3 mm Hg), maximal placebo corrected fall of 12.5 mm Hg at 10 h post-dose, p = 0.005. No significant change occurred in ICA flow, MCAv or CBF measured by SPECT: change from baseline in symptomatic hemisphere CBF was -0.02 (SD 3.11) ml/100 g/min (treated group) compared with 0 (SD 3.01) (placebo group). Similarly, no significant change was observed in cortical CBF. Mean within-group change in GFR was 2.7 +/- 10.1 in the treated group and -4.3 +/- 6.7 in the placebo group (p = NS). DISCUSSION: Antihypertensive therapy with perindopril may be introduced in the first week after mild ischaemic stroke in normotensive patients without affecting global or regional CBF or affecting GFR.

The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke.

BACKGROUND: Secondary prevention of stroke with antihypertensive drugs is now standard practice, but it is unclear how soon after a cerebrovascular event antihypertensive therapy should be initiated or re-started. Due to impaired cerebral autoregulation, changes in systemic blood pressure may be reflected in cerebral perfusion, especially in hypertensive patients immediately post-stroke. Conversely, early initiation in hospital may better assure continued long-term treatment. We have investigated the effect of the angiotensin II receptor antagonist (ARA) losartan on mean arterial blood pressure (MABP), global and focal cerebral blood flow (CBF), and glomerular filtration rate (GFR) in hypertensive patients 2-7 days after stroke. METHODS: Twenty-four patients without occlusive carotid disease but with MABP between 110 and 145 mmHg were studied within 2-7 days of ischaemic stroke/transient ischaemic attack (TIA). They were randomized to receive either placebo or losartan (25 or 50 mg daily). MABP and internal carotid artery (ICA) flow were measured at baseline, over the following 24 h and at 2 weeks. Brain hexamethylpropyleneamine oxime single photon emission computed tomography (HMPAO SPECT) was performed before dosing and at the estimated time of peak drug effect (6-8 h after the first dose). GFR was measured at baseline and at 2 weeks. RESULTS: The mean National Institutes of Health (NIH) score of randomized patients was 2.6; losartan was generally well tolerated and no patient suffered a deterioration in neurological function. A mean placebo-corrected intra-subject reduction in MABP of 9.5 mmHg was observed in treated patients from 1-12 h (P = 0.0001), with a maximal fall of 18.1 mmHg at 9 h post-dose (P = 0.002). No change occurred in ICA flow, or cortical or hemispheric CBF measured by HMPAO SPECT. No significant change in GFR was seen within or between groups. DISCUSSION: Losartan may be introduced within 2-7 days of mild stroke in hypertensive patients in whom significant carotid occlusive disease has been excluded without affecting global or regional CBF, or affecting GFR.

Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.

Twenty-six patients who had undergone recent surgery for differentiated thyroid cancer were investigated using iodine-131 iodide (120 MBq). Uptake in the thyroid bed was measured at 3 days using a dual-head gamma camera. An ablation activity of 131I iodide (4,000 MBq) was administered 3-38 (median 14) days later and uptake in the thyroid bed measured once or twice, 1-3 days post therapy. For measurements post therapy, the gamma camera was operated in the high-count rate mode with appropriate correction factors to compensate for any count loss. A further 16 patients were given iodine-123 iodide (200 MBq) as the diagnostic agent and uptake was measured at 24 h. The ablation activity was administered 5-47 (median 19) days later and uptake again measured at 24 h. In some cases, a further measurement of uptake was made within the period 1-3 days post therapy. Reduced uptake of the therapeutic administration ( P<0.001) was observed in all 26 patients given diagnostic 131I, with a median value of 32.8% (range 6%-93%) of the uptake in the diagnostic study. In the patients given diagnostic 123I, reduced uptake of the ablative radioiodine was observed in 15 of the 16 patients ( P<0.001), and overall the median value was 58.8% (range 17%-130%) of the diagnostic uptake. In one case the uptake post therapy was increased. The stunning observed in the group given 123I was significantly less ( P<0.001) than in the group given 131I. In the patients given diagnostic 131I, stunning appeared to increase in severity the longer the time interval between the diagnostic and therapeutic radionuclides, for intervals up to 25 days. Thereafter, there seemed to be some recovery of uptake capability. Overall there was no evidence of a large rapid loss of radionuclide from the thyroid bed 1-3 days post therapy. The stunning observed using 123I could not be explained by errors in the estimation of relative uptake due to different tissue absorption of the 131I and 123I photons, nor by the radiation dose delivered by the 123I. However, the ablative 131I itself may cause stunning because the cumulated activity, over the first few hours of uptake, is not insignificant when compared with all the cumulated activity from a diagnostic administration of 131I. The resultant radiation dose to the thyroid remnant, as the therapeutic radioiodine is being taken up, may be sufficient to inhibit the uptake process, thus leading to a reduction in maximum uptake when compared with that of a diagnostic activity of radioiodine.